1651Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
نویسندگان
چکیده
Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease Yanina Dubrovskaya, PharmD; Justin Siegfried, PharmD; Thomas Flagiello; Marco R. Scipione PharmD; Donald Chen, MD; Michael Phillips, MD; John Papadopoulos, PharmD; Amar Safdar, MD; Department of Pharmacy, New York University Langone Medical Center, New York, NY; Pharmacy, New York University Langone Medical Center, New York, NY; New York University Medical Center, New York, NY; Department of Pharmacy, New York University Langone Medical Center, New York, NY; Infection Prevention and Control, New York University Langone Medical Center, New York, NY; Infectious Diseases and Immunology, New York University Langone Medical Center, New York, NY
منابع مشابه
Clostridium difficile infection: a review of current and emerging therapies.
Clostridium difficile (C. difficile) infection (CDI) is the most common cause of -healthcare-associated infections in US hospitals. The epidemic strain NAP1/BI/ribotype 027 accounts for outbreaks worldwide, with increasing mortality and severity. CDI is acquired from an endogenous source or from spores in the environment, most easily acquired during the hospital stay. The use of antimicrobials ...
متن کاملFidaxomicin: a new option for the treatment of Clostridium difficile infection.
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and metronidazole, are both associated with high rates of recurrence of infection. Hence there is a need for new treatment options. The novel oral macrocyclic antibiotic fidaxomicin (previously known as PAR-101, OPT-80 and difimicin) was recently approved in the USA and in Europe fo...
متن کامل1659Relapse vs Reinfection. Evaluation of Clostridium difficile Isolates from Incident and Recurrent Infections, Minnesota 2009-2011
Background. Recurrent Clostridium difficile infections (CDI) can be challenging. Recent studies suggest patients with recurrent infections are more likely to have a relapse of their previous strain type than be infected with a new strain of C. difficile, particularly those patients infected with the NAP1 strain. We used PFGE to type and compare 2009-2011 incident and recurrent isolates collecte...
متن کاملRational Therapy of Clostridium difficile Infections
BACKGROUND Clostridium difficile infections (CDI) are increasingly important in patients with antibiotic treatments, ranging from mild, self-limiting to severe, life-threatening disease. Currently, diagnostic algorithms and treatment guidelines are being adapted to novel tests and therapeutic options for recurrent CDI. METHODS A systematic literature search using the terms 'Clostridium diffic...
متن کاملFidaxomicin: A novel agent for the treatment of Clostridium difficile infection
BACKGROUND Due to the limitations of existing treatment options for Clostridium difficile infection (CDI), new therapies are needed. OBJECTIVE To review the available data on fidaxomicin regarding chemistry, mechanisms of action and resistance, in vitro activity, pharmacokinetic and pharmacodynamic properties, efficacy and safety in clinical trials, and place in therapy. METHODS A search of...
متن کامل